Carole De Meester
About Carole De Meester
Carole De Meester is a Senior Regulatory Specialist at Bristol-Myers Squibb and a Senior Regulatory Affairs Associate at Promethera Biosciences, with extensive experience in global regulatory sciences and a PhD in Biomedical and Pharmaceutical Sciences.
Current Position at Bristol-Myers Squibb
Carole De Meester is currently serving as a Senior Regulatory Specialist, Global Regulatory Sciences - ERPM at Bristol-Myers Squibb. She joined the company in March 2018 and is responsible for overseeing regulatory affairs within the European market. Her role involves ensuring compliance with regulatory requirements, preparing regulatory submissions, and interacting with health authorities to support product development and approval processes.
Current Role at Promethera Biosciences
In addition to her role at Bristol-Myers Squibb, Carole De Meester works as a Senior Regulatory Affairs Associate at Promethera Biosciences. She contributes her expertise to the regulatory affairs team, focusing primarily on cell therapy products. Her responsibilities include managing regulatory submissions, compiling documentation, and ensuring products meet regulatory standards.
Experience at Promethera Biosciences
Carole De Meester has extensive experience at Promethera Biosciences, having previously served as a Regulatory Affairs Associate from 2012 to 2015. Over her tenure, she has accumulated over five years of experience in regulatory affairs within Promethera. Her work primarily involved regulatory matters concerning cell therapy products, showcasing her expertise in navigating complex regulatory landscapes.
Educational Background
Carole De Meester holds a PhD in Biomedical and Pharmaceutical Sciences from Université Catholique de Louvain, where she studied from 2006 to 2012. Additionally, she has obtained a master's degree from Université Catholique de Louvain, having studied there from 2000 to 2004. She also studied at the Ludwig Institute for Cancer Research and Université de Namur between 2004 and 2006, enriching her academic and scientific foundation in biomedical research.